PHKB Inhibitors
hemical inhibitors classified as PHKB inhibitors encompass a diverse group of compounds that can influence the activity of PHKB through indirect mechanisms. PHKB, being a part of the glycogenolysis pathway, is susceptible to alterations in the regulation of this pathway. The compounds listed are not direct inhibitors of PHKB but can affect the enzyme's activity by modulating signaling pathways and enzymes that are upstream or downstream in the glycogen metabolism pathway.
For example, metformin, AICAR, and rapamycin target AMPK, a key regulator of energy homeostasis and glycogen metabolism. Activation of AMPK can lead to reduced glycogenolysis, and therefore, a decrease in PHKB activity. H-89 and propranolol act by inhibiting PKA, which is responsible for the activation of glycogen phosphorylase, the enzyme that PHKB activates. By inhibiting PKA, these compounds can reduce the phosphorylation and activation of glycogen phosphorylase, leading to an indirect decrease in PHKB activity. Lithium chloride and dorsomorphin target GSK-3 and AMPK, respectively, both of which have roles in glycogen metabolism. Alloxan's destruction of insulin-secreting cells can lead to a cascade of effects on glycogen synthesis and breakdown, thereby affecting PHKB activity. Compound C and staurospI'm sorry, but I must clarify that my response may have inadvertently implied a level of certainty that is not present in the current state of scientific knowledge. The compounds listed in the table are not direct inhibitors of PHKB but rather affect various signaling pathways or cellular processes that may indirectly influence PHKB activity within the broader context of glycogen metabolism and regulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin-d6, Hydrochloride | 1185166-01-1 | sc-218701 sc-218701A sc-218701B | 1 mg 5 mg 10 mg | $292.00 $822.00 $1540.00 | 1 | |
Metformin activates AMP-activated protein kinase (AMPK), which can inhibit glycogen synthase activity, potentially leading to reduced PHKB activity due to reduced demand for glycogen breakdown. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTORC1, which can lead to activation of AMPK, subsequently inhibiting glycogen synthesis and potentially decreasing PHKB activity as a result. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium acts on glycogen synthase kinase 3 (GSK-3), which is involved in glycogen metabolism. By modulating GSK-3 activity, lithium chloride can indirectly influence PHKB activity. | ||||||
Alloxan monohydrate | 2244-11-3 | sc-254940 | 10 g | $54.00 | ||
Alloxan selectively destroys insulin-producing cells in the pancreas. Disruption of insulin signaling can affect glycogen synthesis and breakdown, thus potentially influencing PHKB activity. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Compound C is another inhibitor of AMPK. Inhibition of AMPK can alter glycogen metabolism and indirectly affect PHKB activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor, which can nonspecifically inhibit kinases involved in glycogen metabolism, thereby potentially affecting PHKB activity. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR is an analog of adenosine monophosphate that can activate AMPK, leading to altered glycogen metabolism and potential indirect inhibition of PHKB. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine affects lysosomal function and autophagy, processes which can also affect glycogen metabolism. Through this mechanism, it may indirectly modulate PHKB activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cyclic AMP and activation of PKA, which can lead to phosphorylation and activation of glycogen phosphorylase, potentially decreasing PHKB activity due to feedback inhibition. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol blocks beta-adrenergic receptors, which can decrease PKA activity and subsequent glycogenolysis, thereby indirectly inhibiting PHKB activity. | ||||||